{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:36:58Z","timestamp":1763037418546},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.2169\/internalmedicine.4232-19","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T22:04:00Z","timestamp":1583964240000},"page":"1433-1435","source":"Crossref","is-referenced-by-count":4,"title":["Whole-brain Radiation and Pembrolizumab Treatment for a Non-small-cell Lung Cancer Patient with Meningeal Carcinomatosis Lacking Driver Oncogenes Led to a Long-term Survival"],"prefix":"10.2169","volume":"59","author":[{"given":"Koki","family":"Nakashima","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Demura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Oi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mio","family":"Tabata","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shiozaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Akai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamotsu","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Schapira E, Hubbeling H, Yeap BY, et al. Improved overall survival and locoregional disease control with concurrent PD-1 pathway inhibitors and stereotactic radiosurgery for lung cancer patients with brain metasitases. Int J Radiat Biol Phys 101: 624-629, 2018.","DOI":"10.1016\/j.ijrobp.2018.02.175"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Chen L, Douglass J, Kleinberg L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in Non-small cell lung cancer, Melanoma, and Renal cell carcinoma. Int J Radiat Oncol Biol Phys 100: 916-925, 2018.","DOI":"10.1016\/j.ijrobp.2017.11.041"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer Treat Rev 25: 103-119, 1999.","DOI":"10.1053\/ctrv.1999.0119"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumor: experience with 90 patients. Cancer 49: 759-772, 1982.","DOI":"10.1002\/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7"},{"key":"5","unstructured":"5. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 55: 506-512, 1998."},{"key":"6","unstructured":"6. Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era. Cancer Treat Rev 53: 128-137, 2017."},{"key":"7","unstructured":"7. Tamiya A, Tamiya M, Nishihara T, et al. Cerebrospinal fluid penetration rate and efficacy of Afatinib in patients with EGFR mutation-positive non-small cell lung cancer with leptomeningeal carcinomatosis: a multicenter prospective study. Anticancer Res 37: 4177-4182, 2017."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Saboundji K, Auliac JB, P\u00e9rol M, et al. Efficacy of Osimertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastases pretreated with EGFR-tyrosine kinase inhibitors. Target Oncol 13: 501-507, 2018.","DOI":"10.1007\/s11523-018-0581-2"},{"key":"9","unstructured":"9. Li H, Yu T, Haang M, et al. Treatment response to Osimertinib in EGFR-mutated leptomeningieal metasitases from non-small cell lung cancer: a case series. Onco Targets Ther 12: 7785-7790, 2019."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol 25: 103-114, 2018.","DOI":"10.3747\/co.25.3733"},{"key":"11","first-page":"e1057388","volume":"9","author":"AS Berghoff","year":"2015","unstructured":"11. Berghoff AS, Fuchs E, Ricken G, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. Oncoimmunology 9: e1057388, 2015.","journal-title":"OncoImmunology","ISSN":"http:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"12","unstructured":"12. Bergohff AS, Inan C, Ricken G, et al. 1324p Tumor-infiltrating lymphocytes (TILS) and PD-L1 expression in non-small cell lung cancer brain metastasis (BM) and matched primary tumors (PT). Ann Oncol 25: iv465-iv466, 2014."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bergohff AS, Ricken G, Wilhelm D, et al. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastasis of small cell lung cancer (SCLC). J Neurooncol 130: 19-29, 2016.","DOI":"10.1007\/s11060-016-2216-8"},{"key":"14","unstructured":"14. Lois AL. Monoclonal antibodyes in neuro-oncology: getting past the blood-brain barrier. mAbs 3: 153-160, 2011."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Saunders NR, Ek CJ, Habgood MD, et al. Barriers in the brain. Trends Neurosci 31: 270-286, 2008.","DOI":"10.1016\/j.tins.2008.03.003"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Eyal S, Hisao P, Unadkat JD. Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123: 80-104, 2009.","DOI":"10.1016\/j.pharmthera.2009.03.017"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bidoli P, Chiari R, Catino A, et al. Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolmab Expanded Access Programme (EAP) in Italy. Ann Oncol 27: 1228, 2016.","DOI":"10.1093\/annonc\/mdw383.28"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Goldberg S, Mahajan A, Herbst R, et al. Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. J Clin Oncol 36 (suppl 15): 2009, 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.2009"},{"key":"19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","volume":"129","author":"L Crino","year":"2019","unstructured":"19. Crino L, Bronte G, Bidoli P, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 129: 35-40, 2019.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Suneel DK, Priya UK. Immune checkpoint inhibitors for the treatment of central nervous system (CNS) metastatic disease. Front Oncol 8: 414, 2018.","DOI":"10.3389\/fonc.2018.00414"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74: 5458-5468, 2014.","DOI":"10.1158\/0008-5472.CAN-14-1258"},{"key":"22","unstructured":"22. Hodge JW, Guha C, Neefjes J, et al. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology 22: 1064-1070, 2008."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Weichselbaum RR, Liang H, Deng L, et al. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14: 365-379, 2017.","DOI":"10.1038\/nrclinonc.2016.211"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2: 831-838, 2014.","DOI":"10.1158\/2326-6066.CIR-14-0069"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124: 687-695, 2014.","DOI":"10.1172\/JCI67313"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/11\/59_4232-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T03:42:24Z","timestamp":1591414944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/11\/59_4232-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4232-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}